Skip to main content

Advertisement

Table 6 Comparison of symptomatic DVT incidence between IgG-class anti-PF4/heparin Ab seroconverted and non-seroconverted patients

From: IgG-class anti-PF4/heparin antibodies and symptomatic DVT in orthopedic surgery patients receiving different anti-thromboembolic prophylaxis therapeutics

  Incidence of symptomatic DVT (%)   
Drug seroconverted non-seroconverted Odds ratio (95%CI) p value
UFH 11/34(32.4%) 5/70(7.1%) 6.217 (1.951-19.816) 0.001
LMWH 3/9(33.3%) 11/86(12.8%) 3.409 (0.743-15.642) 0.125
Fondaparinux 3/12(25.0%) 5/69(7.2%) 4.267 (0.868-20.972) 0.092
Others 3/19(15.8%) 15/75(20.0%) 0.750 (0.193-2.913) 0.481
  1. Abbreviations: DVT; deep vein thrombosis, UFH; unfractionated heparin, LMWH; low-molecular weight heparin, 95%CI; confidence interval